Related Experiment Video

Updated: Jun 19, 2026

Pluripotent Stem Cell Derived Cardiac Cells for Myocardial Repair
06:37

Pluripotent Stem Cell Derived Cardiac Cells for Myocardial Repair

Published on: February 3, 2017

Drawbacks to stem cell therapy in cardiovascular diseases

Chao-Hung Wang1, Wen-Jin Cherng, Subodh Verma

  • 1Chang Gung University College of Medicine, Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital, 222 Mai-Chin Road, Keelung, Taiwan. bearty@adm.cgmh.org.tw

Future Cardiology
|October 7, 2009
PubMed

Insights

Stem cell therapy shows promise for cardiovascular diseases, but safety concerns like tumorigenesis and arrhythmogenesis must be addressed. Research into medical, genetic, and purification techniques aims to overcome these hurdles for future clinical applications.

Area of Science:

  • Regenerative Medicine
  • Cardiovascular Research
  • Cellular Therapy

Background:

  • Stem cells offer potential for repairing cardiovascular disease-related tissue damage.
  • Preclinical success has been tempered by safety concerns and skepticism regarding cellular therapy.
  • Current candidates for cardiovascular cell therapy include embryonic stem cells, skeletal myoblasts, bone marrow-derived stem cells, and mesenchymal stem cells.

Purpose of the Study:

  • To review the potential of stem cell therapy for end-stage cardiovascular diseases.
  • To identify and discuss safety concerns associated with stem cell transplantation in cardiovascular applications.
  • To explore strategies for overcoming safety issues to enable large-scale clinical trials.

Main Methods:

  • Review of existing literature on stem cell therapy for cardiovascular diseases.
  • Identification of safety concerns: atherogenesis, restenosis, tumorigenesis, metastasis, cytokine complications, and arrhythmogenesis.
  • Discussion of potential solutions including medical/gene manipulation, cell purification, antiarrhythmic design, and natural constructs.

Main Results:

  • Several safety concerns require clarification before widespread clinical application of stem cell therapy.
  • Potential strategies exist to mitigate risks such as tumorigenesis and arrhythmogenesis.
  • Addressing safety issues is crucial for realizing the therapeutic potential of stem cells in cardiology.

Conclusions:

  • Stem cell therapy holds significant promise for treating cardiovascular diseases.
  • Overcoming safety concerns is paramount for the successful translation of stem cell therapies.
  • Continued research into safety and efficacy will pave the way for future clinical use in the next decade.

More Related Videos

Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy11:51

Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy

Published on: March 1, 2016

Assessing Stem Cell DNA Integrity for Cardiac Cell Therapy10:16

Assessing Stem Cell DNA Integrity for Cardiac Cell Therapy

Published on: January 25, 2019

Related Concept Videos

Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Stem Cell Culture01:17

Stem Cell Culture

Stem cell research aims to find ways to use stem cells to regenerate and repair cellular damage. Over time, most adult cells undergo the wear and tear of aging and lose their ability to divide and repair themselves. Stem cells do not display a particular morphology or function. Adult stem cells, which exist as a small subset of cells in most tissues, keep dividing and can differentiate into a number of specialized cells generally formed by that tissue. These cells enable the body to renew and...
Embryonic Stem Cells00:57

Embryonic Stem Cells

Embryonic stem (ES) cells were first discovered in mice in 1981 by Martin Evans. In 1998, James Thomson identified a method to isolate embryonic stem cells from humans. Human embryonic stem cells (hESCs) are obtained from 3-5 day old embryos that remain unused after an in vitro fertilization procedure.
ES cells are grown in a culture medium where they can divide indefinitely, creating ES cell lines. Under certain conditions, ES cells can differentiate, either spontaneously into a variety of...
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...
Induced Pluripotent Stem Cells01:13

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different types of cells. Ordinarily, cells that have differentiated into a specific cell type are post-mitotic—that is, they no longer divide. However, scientists have found a way to reprogram these mature cells so that they “de-differentiate” and return to an unspecialized, proliferative state. These cells are also pluripotent like embryonic stem cells—able to produce all cell types—and are therefore called induced pluripotent stem...
Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their access...